20 June 2024
MPP’s three key areas of impact – uptake, economic and health – all show that MPP’s approach is transforming the lives of millions in low- and middle-income countries.
Geneva – The Medicines Patent Pool (MPP), is delighted to publish today its 2023 annual report Accelerating Access Through Community Partnership. While paying tribute to the tremendous contribution that Civil Society has brought to MPP’s work, the report demonstrates beyond question that MPP’s model of voluntary licensing is not only improving the lives of millions across the world, but should be further expanded to encompass many different disease areas.
The report also lays great emphasis on the value of partnership, a core element of MPP’s approach. An important milestone for MPP in 2023 was the formal establishment of the Community Advisory Panel (CAP), a roster of 31 experts all closely affected by diseases relating to MPP’s focus. The CAP now provides MPP with advice on specific disease areas. This will help guide MPP on the medical needs of those living in low- and middle-income countries (LMICs), and, crucially, foster even greater transparency in decision-making.
Charles Gore, MPP’s Executive Director said: “In 2023 we launched our three-year Strategy, which immediately saw us signing a number of licence and sublicence agreements. More than 43 billion doses of treatment have been supplied though MPP’s licences in LMICs. This is an incredible figure, and proof again that MPP’s model of voluntary licensing is a win-win-win for all concerned: for originator and generic pharmaceutical companies, governments and health agencies, but above all for those from LMICs who need and deserve the best medicines and treatments available. It is a model that has proved itself and my hope now is that it will inspire others as a model for greater access for other disease areas and medicines on the WHO Essential Medicines List.”
MPP’s progress between its inception in 2010 and the end of 2023 has been considerable. The figures presented below have been verified by leading auditors KPMG, and show that since 2010:
Further key milestones for 2023 include:
Access MPP’s 2023 Annual Report
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.